DiscoverMedlines
Medlines

Medlines

Author: Human Content, Inc.

Subscribed: 130Played: 897
Share

Description

Healthcare is changing at breakneck speed, and let's face it, staying informed is getting harder by the day. If only there were a way to get the industry news you need in less time than it takes to get prior auth approved. (Spoiler: There is.)


Every Friday, start your day with Dr. Will Flanary (aka Dr. Glaucomflecken), Dr. Alok Patel, Dr. Jen Lincoln, Adam Rose, and Eva Johnson as they bring you the week's most important headlines across clinical care, health policy, groundbreaking publications, medical pop culture, and more. Presented with clear, unbiased, fact-first reporting made strictly for healthcare professionals, by healthcare professionals.


Prepare to wow your colleagues with how informed you are, all without risking another evening doom-scrolling through 5% actual news and 95% videos of, well, if you know you know. 


Medicine moves fast... So do we! 




Learn More: www.medlinespod.com




Medlines is A Human Content Production

21 Episodes
Reverse
Friday, November 13, 2026 In today's episode, Dr. Jennifer Lincoln (@drjenniferlincoln) & Eva Johnson cover two large heart drug trials that lowered markers but not events. They break down Lp(a)HORIZON, which tested pelacarsen, and ZEUS, which tested ziltivekimab. They explain why moving a risk marker is not the same as changing outcomes. Plus: they also discuss an FDA investigation into tumors after the SMA gene therapy Zolgensma, what monitoring may mean for practice, an NFL star's scary neck injury, and more.  Coverage Timeline: (00:00) This Week’s Headlines (01:44) Pelacarsen: Big Drop, No Benefit (03:03) ZEUS Falls Flat (05:24) Gene Therapy’s Tumor Risk (08:05) Plasma Hack, AI Prior Auth & Statin Nudges (09:45) Jack Campbell’s Recovery Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email [email protected]. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
Friday, November 6, 2026  In today's episode, Dr. Will Flanary (@drglaucomflecken) & Adam Rose (@adjoro) cover a new JAMA Network Open estimate that 74.5 percent of deceased former NFL players had CTE after correcting for brain bank selection bias. They break down how researchers modeled donation bias and why the finding still cannot estimate risk for living players. They also dig into how the NFL and players association responded and what it means for counseling patients on head injury risk. Plus: they also discuss the 2026 midterm election results in which several doctors won their races, CVS splitting up, a major dialysis trial that stopped early, and more.  Coverage Timeline: (00:00) Intro (01:27) CTE Among Former NFL Players (05:30) French ICU Dialysis Trial (09:09) 2026 Midterm Result (13:05) CVS Health Split  (14:30) Phone Location Data Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email [email protected]. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
Friday, October 30, 2026  In today's episode, Dr. Jennifer Lincoln (@drjenniferlincoln) & Eva Johnson cover full phase three results for a Lyme disease vaccine, and Psychiatry Boot Camp host Dr. Mark Mullen pays a visit. They break down a new once monthly olanzapine shot for schizophrenia. Plus: a dementia study built on a 1972 British school reform, why Christina Applegate says her MS diagnosis was wrong, and GLP-1 drugs may affect drinking habits in the UK. Thank you to guest anchor Dr. Mark Mullen! Check out his podcast Psychiatry Boot Camp, available every other Monday on YouTube and all your favorite podcast apps. To learn more, visit psychiatrybootcamp.com Coverage Timeline: (0:00) Intro (1:26) Lyme Disease Vaccine (3:31) Vaccine Safety & History (5:07) Schizophrenia Treatment (8:26) School & Dementia Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email [email protected].  Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources  Medlines is a Human Content Production
Friday, October 23, 2026  In today's episode, Dr. Alok Patel (@alokpatelmd) & Adam Rose (@adjoro) cover a phase three trial of nicotinamide riboside in early Parkinson disease. Over 52 weeks, the supplement boosted NAD metabolism but showed no clinical benefit, raising questions for NAD boosting strategies. They also walk through a large hospital comparison of phenobarbital and diazepam for alcohol withdrawal, with similar stays and ventilation rates and fewer self directed discharges on phenobarbital, and why diazepam protocols may stay the course pending randomized trials. Plus: they also discuss national measles trends, FDA warning letters to Amazon and Walmart, and more.  Coverage Timeline: (00:00) Intro (01:05) NR Supplement Trial for Parkinson's (03:01) NAD Supplements & Influencer Hype (04:49) Phenobarbital vs. Diazepam (07:30) Measles Surge in US (08:27) New Sunscreen Ingredient BEMT (09:01) Blood Clots Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email [email protected].  Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources  Medlines is a Human Content Production
Friday, October 16, 2026  In today's episode, Dr. Alok Patel (@alokpatelmd) & Eva Johnson cover the FDA clearance of Motivista as the first prescription app for negative symptoms of schizophrenia. They break down the 16 week CONVOKE trial and what a 2.6 point edge over a control app means for stable patients on antipsychotics. They also review new ACP guidance placing menopausal hormone therapy first for hot flashes and night sweats, with second and third line options. Plus: they discuss early feasibility data on a medical AI chatbot for pre visit histories, new federal recommendations on concentrated kratom products, and more.  Coverage Timeline: (00:00) Intro  (01:08) Schizophrenia App Cleared (03:50) Hot Flashes Guidance (04:47) Dogs & Sleep Study (06:51) AI In Urgent Care (08:37) Awards & Dahlias Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email [email protected].  Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources  Medlines is a Human Content Production
loading
Comments